Loading
A phase 1/2 trial of Cyclophosphamide, Fludarabine and EB-CAR30-NK in thymoma and thymic carcinoma, run by Beijing Biotech, now recruiting.
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma is a phase 1/2 interventional study registered as NCT07598955 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-06-14. Interventions recorded: Cyclophosphamide, Fludarabine, EB-CAR30-NK, EB-CAR5-NK, EB-CARMSLN-NK and Rimiducid (AP1903).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Thymic carcinoma, Thymoma and thymic carcinoma and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/